Simple Summary Thymic carcinoma is identified as thoracic neoplasm having low sensitivity
to systemic chemotherapy. As first-line setting, platinum-based chemotherapy is …

Objective For rarity of thymic carcinoma, no definitive chemotherapeutic regimen has been
established in second-or further-line settings. The aim of this study was to evaluate the …

Background The prognostic factors and the efficacy of first‐line chemotherapy remain
unclear in patients with advanced thymic carcinoma. Materials and Methods We conducted …

Background Clinical efficacy of second-and later-line chemotherapy for patients with thymic
carcinoma previously treated with chemotherapy remains uncertain; limited data are …

Thymic carcinoma (TC) is a rare cancer and patients failing initial chemotherapy
(relapse/refractory) face limited therapeutic options given no approved options or consensus …

Platinum-based chemotherapy is the de facto standard treatment for metastatic or
unresectable thymic carcinoma. The optimal chemotherapy regimen has not yet been …

Thymic carcinoma (TC) is a rare cancer with minimal evidence of survival following palliative‐
intent chemotherapy. Sunitinib, everolimus, and pembrolizumab have been proposed as …

Background: Optimal chemotherapeutic regimen in thymic carcinoma remains uncertain and
the efficacy of second line chemotherapy has not been established either. Patients and …

Aims Thymic carcinoma (TC) is a rare form of highly invasive tumors. Currently, the standard
first-line therapy involves paclitaxel plus carboplatin treatment, while the recommended …

Background Currently there is no standard therapy recommended for second‐line treatment
for thymic carcinoma. Our study compared multidrug chemotherapy, single‐agent …